Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

MPTP as a mitochondrial neurotoxic model of Parkinson's disease.

Przedborski S, Tieu K, Perier C, Vila M.

J Bioenerg Biomembr. 2004 Aug;36(4):375-9. Review.

PMID:
15377875
2.

Molecular basis for catecholaminergic neuron diversity.

Grimm J, Mueller A, Hefti F, Rosenthal A.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13891-6. Epub 2004 Sep 7.

3.

Generalized brain and skin proteasome inhibition in Huntington's disease.

Seo H, Sonntag KC, Isacson O.

Ann Neurol. 2004 Sep;56(3):319-28.

PMID:
15349858
4.

N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats.

Krishnamurthi R, Stott S, Maingay M, Faull RL, McCarthy D, Gluckman P, Guan J.

Neuroreport. 2004 Jul 19;15(10):1601-4.

PMID:
15232291
5.

IGF-I prevents glutamate-induced motor neuron programmed cell death.

Vincent AM, Mobley BC, Hiller A, Feldman EL.

Neurobiol Dis. 2004 Jul;16(2):407-16.

PMID:
15193297
6.

Gene regulation and DNA damage in the ageing human brain.

Lu T, Pan Y, Kao SY, Li C, Kohane I, Chan J, Yankner BA.

Nature. 2004 Jun 24;429(6994):883-91. Epub 2004 Jun 9.

PMID:
15190254
7.

Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects.

Dogrukol-Ak D, Tore F, Tuncel N.

Curr Pharm Des. 2004;10(12):1325-40. Review.

PMID:
15134484
8.

Insulin-like growth factor-I, cognition and brain aging.

van Dam PS, Aleman A.

Eur J Pharmacol. 2004 Apr 19;490(1-3):87-95. Review.

PMID:
15094076
9.

Hereditary early-onset Parkinson's disease caused by mutations in PINK1.

Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW.

Science. 2004 May 21;304(5674):1158-60. Epub 2004 Apr 15.

10.

Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.

Reglodi D, Lubics A, Tamás A, Szalontay L, Lengvári I.

Behav Brain Res. 2004 May 5;151(1-2):303-12.

PMID:
15084446
11.

Commentary on "Alpha-synuclein and mitochondria: a tangled skein".

Beal MF.

Exp Neurol. 2004 Apr;186(2):109-11. No abstract available.

PMID:
15026249
12.

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice.

Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J.

J Biol Chem. 2004 Apr 30;279(18):18614-22. Epub 2004 Feb 24.

13.

Multiple risk factors for Parkinson's disease.

Gorell JM, Peterson EL, Rybicki BA, Johnson CC.

J Neurol Sci. 2004 Feb 15;217(2):169-74.

PMID:
14706220
14.
15.

Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein.

Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ.

Science. 2003 Dec 5;302(5651):1769-72.

16.

The mitochondrial transporter family (SLC25): physiological and pathological implications.

Palmieri F.

Pflugers Arch. 2004 Feb;447(5):689-709. Epub 2003 Nov 4. Review.

PMID:
14598172
17.

alpha-Synuclein locus triplication causes Parkinson's disease.

Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K.

Science. 2003 Oct 31;302(5646):841. No abstract available.

18.
19.

Bombesin-like peptides: candidates as diagnostic and therapeutic tools.

Yeğen BC.

Curr Pharm Des. 2003;9(12):1013-22. Review.

PMID:
12678868
20.

Insulin-like growth factor-1 protects human dopaminergic SH-SY5Y cells from salsolinol-induced toxicity.

Shavali S, Ren J, Ebadi M.

Neurosci Lett. 2003 Apr 10;340(2):79-82.

PMID:
12668241
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk